A

s President Trump tweets yet another promise to lower drug prices, a new analysis offers an example of what can happen when the federal government negotiates with manufacturers.

During a 12-month period ended November 2015, the Veterans Choice Program, which was created by the US Department of Veterans Affairs, paid a median price of $12,500 for a month’s supply of Harvoni, a hepatitis C drug sold by Gilead Sciences. Since most patients typically are treated for two to three months, the cost was closer to $25,000 to $37,500 per person, according to the analysis in Medical Care.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Essentially therefore, the VA is “doing more [about prices] with less [ok, fewer]” – food for thought. That said, the law still has to change for Medicare to negotiate.

Recommended Stories

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.